Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 10/20 | 0.47 |
| ▸ | CYP2C8 | P10632 | 6/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 5/20 | 0.40 |
| ▸ | TTR | P02766 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
| ▸ | CA7 | P43166 | 1/20 | 0.37 |
| ▸ | CA9 | Q16790 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30636963 | 1.00 | FFAR1 (0.47) | FFAR1CYP2C8CYP2C9TTRCA1 | |
| SCHEMBL26186779 | 0.84 | DRD2 (0.44) | FFAR1CYP2C8CYP2C9 | |
| SCHEMBL30636931 | 0.84 | DRD2 (0.44) | FFAR1CYP2C8CYP2C9 | |
| SCHEMBL26186789 | 0.84 | DRD2 (0.44) | FFAR1CYP2C8CYP2C9 | |
| SCHEMBL26186918 | 0.84 | DRD2 (0.44) | FFAR1CYP2C8CYP2C9 | |
| SCHEMBL17985242 | 0.81 | MEN1 (0.50) | FFAR1CYP2C8CYP2C9 | |
| SCHEMBL16585100 | 0.81 | MEN1 (0.50) | FFAR1CYP2C8CYP2C9 | |
| SCHEMBL26186810 | 0.81 | FFAR1 (0.40) | FFAR1CYP2C8CYP2C9 | |
| SCHEMBL16585271 | 0.81 | MEN1 (0.50) | FFAR1CYP2C8CYP2C9 | |
| SCHEMBL26567087 | 0.80 | LMNA (0.44) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250250230-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2025-08-07 | — | — | US | disclosed |
| WO-2023199091-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-10-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250250230-A1 | HETEROCYCLIC COMPOUND | HCRTR2, HCRTR1, NPY2R | FFAR1 280/4885CYP2C8 559/4885CYP2C9 681/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.